Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

This article conducts technical analysis and provides forecasts for top trending stocks like Plug Power (PLUG), Uber, and ...

Importantly, Pfizer Inc. (NYSE:PFE) does carry debt. But is this debt a concern to shareholders? We've found 21 US stocks ...

Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of ...

View the latest Pfizer Inc. (PFE) stock price, news, historical charts, analyst ratings and financial information from WSJ.